![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/18896752-655214283-zyversarev-cmyk-jpg-100x63.jpeg)
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC …